Drug
Av7909
Av7909: highest development phase Phase 3, developed by Emergent BioSolutions. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Emergent BioSolutions
Trials
| Drug | Phase | Indication |
|---|---|---|
| AV7909 NCT03877926 | Phase 3 | Anthrax |
| AV7909 NCT01770743 | Phase 2 | Anthrax |
Latest
No recent events.
Follow Av7909 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.